Uses of MY Hep Tablet MY Hep 400mg Tablet is used in the treatment of chronic hepatitis C virus (HCV) infection. How MY Hep Tablet works My hep 400mg tablet is an antiviral medication. It works by lowering a load of hepatitis C virus in the body and removing the virus from the blood over a period of time. In Depth Information on MY Hep Tablet Expert advice for MY Hep Tablet This drug should be used only in combination with Ribavirin or with Pegylated interferon and Ribavirin. Treatment with sofosbuvir is not recommended in patients with severe kidney or liver problems or depression. Do consult your doctor if you are taking amiodarone (used for serious irregular heartbeats). The risk of slow heartbeat may be increased when taken along with Sofosbuvir. Take extreme care to avoid pregnancy in female patients or female partners of male patients who are on treatment with sofosbuvir. Take necessary precautions as sofosbuvir does not prevent the spread of infection to other people through sexual contact, sharing needles, or contact with blood. MYHEP 400MG USES : Sofosbuvir is used with other antiviral medications (such as ribavirin, peginterferon, daclatasvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It works by reducing the amount of hepatitis C virus in your body, which may help your liver recover. MYHEP 400 MG COMMON SIDE EFFECTS : Tiredness, headache, nausea, diarrhea, itchy skin, difficulty sleeping, or irritability may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist. SAFETY INFORMATION (Precautions) : Before taking sofosbuvir, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. What is MyDacla? MyDacla is an antiviral medicine that is used in combination with other medicines to treat hepatitis C in adults. The drug contains the active substance Daclatasvir that blocks the activity of a hepatitis C virus protein called "NS5A", which is essential for virus multiplication. By blocking this protein, the drug stops hepatitis C virus multiplication. There are several genotypes of hepatitis C virus and it has been shown that Daclatasvir is effective against genotypes 1 to 4. How is MyDacla used ? Daclatasvir can only be obtained with a prescription and treatment should be initiated and monitored by a physician experienced in the treatment of patients with chronic hepatitis C. It is available as 30 mg and 60 mg tablets. The usual dose is 60 mg once a day. Daclatasvir should be used in combination with other chronic hepatitis C medications such as sofosbuvir, peginterferon alfa and ribavirin. The combination of medication to be used and the duration of treatment will depend on the hepatitis C virus genotype the patient is infected with and the type of liver disease he or she has, for example, if he has cirrhosis (liver sclerosis) or if the patient's liver is no longer functioning suitable. For more information, see the prospectus. How does MyDacla work? The active substance in MyDacla, daclatasvir, blocks the activity of a hepatitis C virus called "NS5A", which is essential for virus multiplication. Blocking this protein stops the hepatitis C virus multiplication. There are several genotypes of hepatitis C and Daclatasvir has been shown to be effective against genotypes 1 to 4. What benefit has Daclatasvir shown during the studies? In a major study involving 211 adults, Daclatasvir used in combination with sofosbuvir (with or without ribavirin) has been shown to be effective in eliminating hepatitis C virus from the blood. Patients in the study were infected with genotypes 1, 2 or 3 and all received treatment for 12 or 24 weeks. Most patients had not been previously treated for hepatitis C, Although some were infected with standard 1-drug resistant genotype (consisting of telaprevir or boceprevir - the so-called NS3 / 4A inhibitors - in combination with peginterferon alfa and ribavirin). Approximately 99% of patients with genotype 1 (125 out of 126), 96% of patients with genotype 2 (25 out of 26) and 89% of patients with genotype 3 (16 out of 18) Of the virus in the blood at 12 weeks after the end of the planned treatment. Additional studies involving patients with genotype 4 indicate that Daclatasvir is as effective against genotype 4 as against genotype 1. What are the associated risks? The most common side effects reported with Daclatasvir in combination with sofosbuvir, with or without ribavirin, Are exhaustion (fatigue), nausea and headache. For the full list of side effects reported with Daclatasvir, see the Package Leaflet. Daclatasvir is contraindicated with certain medicines that may reduce its effects. For more information on medicines that should not be taken with Daclatasvir, see the Package Leaflet.
Disclaimer : This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.